Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Latest Information Update: 01 Apr 2025
At a glance
- Drugs IC19-chimeric-antigen-receptor-T-cell-therapy-Beijing-Immunochina-Medical-Science-and-Technology (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 31 Mar 2025 New trial record